ArticleJournal of nanobiotechnology2025
Single-atom Ca nanozyme induces glioma death through Ca
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Perovskite immunoadjuvant: Remodeling the immunosuppressive microenvironment via photothermal catalysis to enhance T-cell recruitment and amplify the immune response.Materials today. Bio · 2026Article
- Overcoming barriers: mechanisms and strategies of nanoparticles in overcoming the blood-brain barrier and drug resistance in glioblastomas.Journal of the Egyptian National Cancer Institute · 2026Review
- Ferroptosis and metabolic reprogramming in the immunosuppressive microenvironment of glioblastoma: emerging mechanisms and novel strategies.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
In recent years, nanozyme-based catalytic therapy for tumors has garnered extensive attention. They combine the properties of nanomaterials and enzymes, precisely mimicking the structure of natural enzymes and exhibiting highly efficient catalytic ability. While nanozymes exert favorable catalytic therapeutic effects in the treatment of most tumors, their application in gliomas is limited by the unique physiological environment and the blood-brain barrier. In this study, a calcium atom nanozyme (CaCN) with peroxidase-like (POD-like) properties was developed. It can induce multiple cell death mechanisms in glioma cells, such as calcium overload and ferroptosis, and synergistically modulate the immune microenvironment. After being functionalized with transferrin (TF) targeting ligands and polyethylene glycol (PEG), it selectively crosses the blood-brain barrier, thereby inhibiting the malignant progression of glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.